Article
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.
Advances in therapy - 1 Aug 2024
Patel Jyoti, Meng Jie, Le Hoa, Tanaka Yoko, Phani Sudarshan, Salas Maribel, Wu Chuntao, Sternberg David, Esker Stephen, Anderson Jeffrey P, Crowley Aaron, Zhou Summera Q, Lieb Camryn, Sun Haiyan, Doan Quan V, Santhanagopal Anu, Reckamp Karen L
Abstract excerpt
INTRODUCTION: For patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after osimertinib and platinum-based chemotherapy (PBC), no uniformly accepted standard of care exists. Moreover, limited efficacy of standard treatments indicates an unmet medical need, which is being addressed by ongoing clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.